Healthcare Equipment and Supplies
Company Overview of Sebacia, Inc.
Sebacia, Inc., a medical device company, focuses on creating light-based therapies for the treatment of dermatological conditions. It is developing a device for the treatment of acne. Sebacia, Inc. was formerly known as TIF Acquisition XII, Inc. The company was incorporated in 2008 and is based in Duluth, Georgia.
2905 Premiere Parkway
Duluth, GA 30097
Founded in 2008
Key Executives for Sebacia, Inc.
Chief Executive Officer, President and Director
Vice President of Engineering and Program Management
Compensation as of Fiscal Year 2015.
Sebacia, Inc. Key Developments
Sebacia, Inc. Announces Completion of Enrollment in Pivotal U.S. Clinical Trial for Severe Acne
Oct 7 15
Sebacia, Inc. announced completion of enrollment in the U.S. randomized pivotal clinical trial investigating the use of the Sebacia Acne Treatment System, an investigational device that uses a combination of gold microparticles and laser energy to target acne. Unlike acne treatments that require daily treatments with lotions or pills, the Sebacia System is intended to treat acne through a simple, physician-guided, in-office procedure. Sebacia's proprietary gold microparticles are designed to be used with existing dermatologic lasers to heat the sebaceous glands and follicles to treat acne. The pivotal clinical study is a randomized, blinded, controlled assessment to determine the safety and effectiveness of the Sebacia Acne Treatment System in the treatment of inflammatory acne vulgaris. A total of 396 people were enrolled with 28 dermatologists across the United States. The studies were designed as parallel assignment with one treatment group and two control groups. The control groups received either Sebacia microparticles without laser treatment or the suspension without Sebacia microparticles with laser treatment. Primary outcome measures are the mean percent change in inflammatory lesion count from baseline to week 12 and the safety and tolerability of the procedure. Secondary outcome measures are the mean absolute change in inflammatory lesion count from baseline to week 12 and success by investigator's global assessment (IGA) at week 12. Success is defined as a two-point decrease from baseline IGA. Although accrual is complete, follow up of participants will continue until December 2015.
Square 1 Bank Announces Credit Facility to Sebacia, Inc
Aug 26 15
Square 1 Bank announced that it has provided a $10 million credit facility to new client Sebacia, Inc. Proceeds will be used to support the company's continued growth.
Sebacia, Inc. Hires Pedro Medrano as Vice President, Engineering and Program Management
Jun 25 15
Sebacia, Inc. hired Pedro Medrano as Vice President, Engineering and Program Management. In his new role, Mr. Medrano will lead commercialization readiness for Sebacia Treatment, a potential new in-office procedure for acne, one of the most common dermatological conditions. The Sebacia Treatment utilizes hair removal lasers, already in routine use among dermatologists, in combination with proprietary Sebacia Gold Microparticles, and is designed to deliver lasting results from a few, simple treatments performed at a dermatologist's office. Prior to joining Sebacia, Mr. Medrano was Director of the Project Management Office for Philips' Nuclear Medicine and Imaging business, responsible for new product development and sustaining programs.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 21, 2015